34
Participants
Start Date
December 14, 2020
Primary Completion Date
February 17, 2023
Study Completion Date
May 5, 2023
EP0057
EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
Olaparib tablets
Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
St. Margit Hospital, Budapest
National Institute of Oncology, Budapest
University of Debrecen Clinical Center, Debrecen
Petz Aladár County Teaching Hospital, Győr
North Shore Hematology Oncology Associates PC DBA New York Cancer and Blood Specialists, East Setauket
University of Rochester Medical Center, Rochester
Magee Women's Hospital of UPMC, Pittsburgh
Emily Couric Clinical Cancer Center, Charlottesville
Duke Cancer Center, Durham
Prisma Health Cancer Institute, Greenville
Augusta University, Augusta
Florida Cancer Specialists and Research Institute, Lady Lake
Sarah Cannon, Nashville
University of California Irvine, Irvine
Massachusetts General Hospital, Boston
Royal Shrewsbury Hospital, Shrewsbury
Addenbrooke's Hospital, Cambridge
University College Hospital, London
Guy's Hospital, London
Hammersmith Hospital, London
Royal Stoke Hospital, Stoke-on-Trent
Lead Sponsor
Ellipses Pharma
INDUSTRY